ES2689071T3 - Régimen de dosificación del compuesto FGF-18 - Google Patents
Régimen de dosificación del compuesto FGF-18 Download PDFInfo
- Publication number
- ES2689071T3 ES2689071T3 ES15706006.2T ES15706006T ES2689071T3 ES 2689071 T3 ES2689071 T3 ES 2689071T3 ES 15706006 T ES15706006 T ES 15706006T ES 2689071 T3 ES2689071 T3 ES 2689071T3
- Authority
- ES
- Spain
- Prior art keywords
- fgf
- joint
- day
- cartilage
- diclofenac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003977 fibroblast growth factor 18 Human genes 0.000 title abstract description 19
- 108090000370 fibroblast growth factor 18 Proteins 0.000 title abstract description 19
- 150000001875 compounds Chemical class 0.000 title abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 8
- 206010061762 Chondropathy Diseases 0.000 abstract description 4
- 208000015100 cartilage disease Diseases 0.000 abstract description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 14
- 229960001259 diclofenac Drugs 0.000 description 14
- 210000003127 knee Anatomy 0.000 description 14
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 10
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 10
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 10
- 229960004238 anakinra Drugs 0.000 description 10
- 210000000845 cartilage Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 239000002260 anti-inflammatory agent Substances 0.000 description 7
- 229940124599 anti-inflammatory drug Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
- 208000013201 Stress fracture Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004353 tibial menisci Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000007353 Hip Osteoarthritis Diseases 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000046824 human IL1RN Human genes 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14000600 | 2014-02-20 | ||
| EP14000600 | 2014-02-20 | ||
| PCT/EP2015/053624 WO2015124727A1 (en) | 2014-02-20 | 2015-02-20 | Fgf-18 compound dosing regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2689071T3 true ES2689071T3 (es) | 2018-11-08 |
Family
ID=50151088
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15706006.2T Active ES2689071T3 (es) | 2014-02-20 | 2015-02-20 | Régimen de dosificación del compuesto FGF-18 |
| ES15707076.4T Active ES2688551T3 (es) | 2014-02-20 | 2015-02-20 | Régimen de dosificación del compuesto FGF-18 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15707076.4T Active ES2688551T3 (es) | 2014-02-20 | 2015-02-20 | Régimen de dosificación del compuesto FGF-18 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9724388B2 (enExample) |
| EP (2) | EP3119417B1 (enExample) |
| JP (2) | JP6431083B2 (enExample) |
| KR (2) | KR102410986B1 (enExample) |
| CN (2) | CN106232622A (enExample) |
| AR (2) | AR099510A1 (enExample) |
| AU (2) | AU2015220773B2 (enExample) |
| BR (2) | BR112016018685A2 (enExample) |
| CA (1) | CA2938791A1 (enExample) |
| DK (2) | DK3107559T3 (enExample) |
| ES (2) | ES2689071T3 (enExample) |
| HR (2) | HRP20181570T1 (enExample) |
| HU (1) | HUE040350T2 (enExample) |
| IL (2) | IL247083B (enExample) |
| LT (2) | LT3107559T (enExample) |
| MX (2) | MX2016010871A (enExample) |
| NZ (1) | NZ723148A (enExample) |
| PL (2) | PL3107559T3 (enExample) |
| PT (2) | PT3119417T (enExample) |
| RS (2) | RS57709B1 (enExample) |
| RU (2) | RU2700582C2 (enExample) |
| SG (2) | SG11201606502YA (enExample) |
| SI (2) | SI3107559T1 (enExample) |
| WO (2) | WO2015124727A1 (enExample) |
| ZA (2) | ZA201605548B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181570T1 (hr) | 2014-02-20 | 2018-11-30 | Merck Patent Gmbh | Režim doziranja spoja fgf-18 |
| ES2698117T3 (es) | 2014-02-20 | 2019-01-31 | Merck Patent Gmbh | Implante que comprende FGF-18 |
| CA2971315C (en) | 2015-01-29 | 2023-02-14 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| LT3419625T (lt) | 2016-02-22 | 2021-07-26 | Novartis Ag | Fxr agonistų panaudojimo būdai |
| LT3687558T (lt) | 2017-09-29 | 2022-06-27 | Merck Patent Gmbh | Metaboliniai biožymenys, skirti atsako į fgf-18 junginį numatymui |
| RS63292B1 (sr) * | 2017-09-29 | 2022-06-30 | Merck Patent Gmbh | Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18 |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
| JP7671249B2 (ja) * | 2019-02-08 | 2025-05-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 変形性関節症が急速に進行するリスクがある患者の治療 |
| KR102920449B1 (ko) * | 2023-03-29 | 2026-02-03 | 주식회사 아이프로테인테라퓨틱스 | 인터류킨-1 수용체 길항제 변이체 및 이의 용도 |
| CN122161846A (zh) * | 2023-10-11 | 2026-06-05 | 四川至善唯新生物科技有限公司 | 治疗关节炎的组合物和方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1551426B1 (en) * | 2002-10-07 | 2014-06-25 | ZymoGenetics, Inc. | Methods of administering fgf18 |
| WO2006014444A1 (en) * | 2004-07-06 | 2006-02-09 | Zymogenetics, Inc. | Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use |
| US20070243132A1 (en) * | 2005-12-22 | 2007-10-18 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| NZ574216A (en) * | 2006-08-25 | 2011-11-25 | Ares Trading Sa | Treatment of cartilage disorders with fgf-18 |
| US8207115B2 (en) * | 2006-08-25 | 2012-06-26 | Ares Trading S.A. | Treatment of cartilage disorders with FGF-18 |
| DE102006043260A1 (de) * | 2006-09-11 | 2008-03-27 | Krones Ag | Etikettieranlage |
| AU2012232658B2 (en) * | 2011-03-22 | 2016-06-09 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| HRP20181570T1 (hr) | 2014-02-20 | 2018-11-30 | Merck Patent Gmbh | Režim doziranja spoja fgf-18 |
| KR102437057B1 (ko) | 2014-02-20 | 2022-08-26 | 메르크 파텐트 게엠베하 | 이식편 이식 및 조직 공학 절차에 있어서의 ｆｇｆ－１８ |
| ES2698117T3 (es) | 2014-02-20 | 2019-01-31 | Merck Patent Gmbh | Implante que comprende FGF-18 |
-
2015
- 2015-02-20 HR HRP20181570TT patent/HRP20181570T1/hr unknown
- 2015-02-20 RU RU2016137292A patent/RU2700582C2/ru active
- 2015-02-20 ES ES15706006.2T patent/ES2689071T3/es active Active
- 2015-02-20 SI SI201530428T patent/SI3107559T1/sl unknown
- 2015-02-20 KR KR1020167025246A patent/KR102410986B1/ko active Active
- 2015-02-20 AU AU2015220773A patent/AU2015220773B2/en active Active
- 2015-02-20 DK DK15706006.2T patent/DK3107559T3/en active
- 2015-02-20 HU HUE15706006A patent/HUE040350T2/hu unknown
- 2015-02-20 AU AU2015220777A patent/AU2015220777B2/en active Active
- 2015-02-20 SI SI201530410T patent/SI3119417T1/sl unknown
- 2015-02-20 ES ES15707076.4T patent/ES2688551T3/es active Active
- 2015-02-20 RS RS20181168A patent/RS57709B1/sr unknown
- 2015-02-20 RU RU2016137289A patent/RU2691946C2/ru active
- 2015-02-20 EP EP15707076.4A patent/EP3119417B1/en active Active
- 2015-02-20 LT LTEP15706006.2T patent/LT3107559T/lt unknown
- 2015-02-20 WO PCT/EP2015/053624 patent/WO2015124727A1/en not_active Ceased
- 2015-02-20 DK DK15707076.4T patent/DK3119417T3/en active
- 2015-02-20 BR BR112016018685A patent/BR112016018685A2/pt not_active Application Discontinuation
- 2015-02-20 US US15/120,134 patent/US9724388B2/en active Active
- 2015-02-20 PT PT15707076T patent/PT3119417T/pt unknown
- 2015-02-20 JP JP2016553329A patent/JP6431083B2/ja active Active
- 2015-02-20 JP JP2016553284A patent/JP6431082B2/ja active Active
- 2015-02-20 SG SG11201606502YA patent/SG11201606502YA/en unknown
- 2015-02-20 MX MX2016010871A patent/MX2016010871A/es active IP Right Grant
- 2015-02-20 AR ARP150100508A patent/AR099510A1/es unknown
- 2015-02-20 NZ NZ723148A patent/NZ723148A/en unknown
- 2015-02-20 KR KR1020167025245A patent/KR102410988B1/ko active Active
- 2015-02-20 WO PCT/EP2015/053631 patent/WO2015124731A1/en not_active Ceased
- 2015-02-20 RS RS20181167A patent/RS57853B1/sr unknown
- 2015-02-20 EP EP15706006.2A patent/EP3107559B1/en active Active
- 2015-02-20 PL PL15706006T patent/PL3107559T3/pl unknown
- 2015-02-20 US US15/120,131 patent/US9889179B2/en active Active
- 2015-02-20 PL PL15707076T patent/PL3119417T3/pl unknown
- 2015-02-20 CA CA2938791A patent/CA2938791A1/en not_active Abandoned
- 2015-02-20 CN CN201580020536.2A patent/CN106232622A/zh active Pending
- 2015-02-20 SG SG11201606505UA patent/SG11201606505UA/en unknown
- 2015-02-20 HR HRP20181572TT patent/HRP20181572T1/hr unknown
- 2015-02-20 MX MX2016010872A patent/MX2016010872A/es active IP Right Grant
- 2015-02-20 LT LTEP15707076.4T patent/LT3119417T/lt unknown
- 2015-02-20 CN CN201580020532.4A patent/CN106456713A/zh active Pending
- 2015-02-20 BR BR112016018696A patent/BR112016018696A2/pt not_active Application Discontinuation
- 2015-02-20 AR ARP150100507A patent/AR099558A1/es unknown
- 2015-02-20 PT PT15706006T patent/PT3107559T/pt unknown
-
2016
- 2016-08-03 IL IL247083A patent/IL247083B/en active IP Right Grant
- 2016-08-03 IL IL247084A patent/IL247084B/en active IP Right Grant
- 2016-08-10 ZA ZA2016/05548A patent/ZA201605548B/en unknown
- 2016-08-10 ZA ZA2016/05547A patent/ZA201605547B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2688551T3 (es) | Régimen de dosificación del compuesto FGF-18 | |
| KR101419961B1 (ko) | Ｆｇｆ-18 로 연골 질환의 치료 | |
| CN101505787B (zh) | 软骨障碍的治疗 | |
| JP7595369B2 (ja) | 変形性関節症の治療に使用するための製剤 | |
| WO2022269001A1 (en) | Pharmaceutical compositions comprising glp-1r agonists | |
| ES2616004T3 (es) | Agente profiláctico y/o agente terapéutico y/o agente supresor de exacerbación para osteortritis de rodilla humana | |
| RU2745453C2 (ru) | Комбинированная композиция, содержащая соединение fgf-18 | |
| CA2938793C (en) | Fgf-18 compound dosing regimen | |
| CN111212652A (zh) | 骨关节炎疼痛的新疗法 | |
| Li | Therapeutic effect of total hip replacement in patients with knee osteoarthritis | |
| HK1231754A1 (zh) | Fgf-18化合物给药方案 | |
| HK1231895A1 (en) | Fgf-18 compound dosing regimen |